Medtronic Plc's SPYRAL Trial Confirms Effectiveness of Symplicity RDN in Hypertension Management
- Medtronic's SPYRAL trial shows significant blood pressure reduction with the Symplicity RDN procedure over three years.
- The trial reports no significant safety issues, reinforcing the long-term safety of Medtronic's innovative treatment.
- Medtronic aims to lead in hypertension management through ongoing research and development of the Symplicity system.
Medtronic's Landmark SPYRAL Trial Results Reinforce Efficacy of Symplicity RDN Procedure
Medtronic plc, a leader in healthcare technology, unveils promising long-term results from its SPYRAL HTN-ON MED randomized clinical trial, spotlighting the effectiveness of the Symplicity™ Spyral renal denervation (RDN) procedure in managing hypertension. Presented at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference, the trial demonstrates that patients who undergo the Symplicity procedure experience significant reductions in blood pressure compared to those receiving sham treatment over a three-year period. Specifically, the data reveals a 14.0 mmHg reduction in 24-hour ambulatory systolic blood pressure (ABPM) for the RDN group, contrasted with a 9.3 mmHg reduction in the sham cohort, a difference that is statistically significant (p=0.0028).
The study's findings extend to office-based measurements as well, where the RDN group shows an 18.5 mmHg decrease in office-based systolic blood pressure (OSBP) versus an 11.7 mmHg reduction in the sham group (p=0.0002). These results not only affirm the efficacy of the Symplicity procedure in lowering blood pressure but also highlight its safety profile. Notably, the study reports no instances of renal artery stenosis greater than 70% among the RDN participants, reinforcing the long-term safety of this innovative treatment. As the trial progresses, co-principal investigator Dr. David Kandzari emphasizes the durability of the blood pressure-lowering effects, suggesting that patients may benefit from sustained management of hypertension through this procedure.
Jason Weidman, senior vice president at Medtronic, underscores the significance of the findings by noting the extensive research backing the Symplicity system, with over 5,000 patients studied and more than 30,000 procedures performed globally. This extensive data not only establishes a high standard for renal denervation but also positions the Symplicity blood pressure procedure as a viable option for patients who continue to struggle with uncontrolled hypertension, even after lifestyle modifications and medical interventions. The implications of these findings are profound, as they may enhance treatment options for millions of patients worldwide who face the challenges of managing high blood pressure.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

